Clinical Report: Extended antiviral therapy may not improve long COVID
Overview
The RECOVER-VITAL trial, a randomized, double-blind, placebo-controlled study, found that nirmatrelvir–ritonavir treatment for up to 25 days did not significantly improve cognitive dysfunction, autonomic dysfunction, or exercise intolerance in long COVID patients compared to placebo. The study included 964 patients, with a median age of 49 years, 67% female, and 78% White, and showed no statistically significant differences in primary or secondary outcomes across treatment groups.
Background
Long COVID presents a significant public health challenge, with many patients experiencing persistent symptoms following SARS-CoV-2 infection. The RECOVER-VITAL trial aimed to evaluate the efficacy of nirmatrelvir–ritonavir, an antiviral therapy, in addressing long COVID symptoms.
Data Highlights
| Outcome | 25-Day Nirmatrelvir-Ritonavir | 15-Day Nirmatrelvir-Ritonavir | Placebo |
|---|---|---|---|
| Cognitive Dysfunction Improvement | 58% | 53% | 55% |
| Autonomic Dysfunction Improvement | 62% | 70% | 70% |
| Exercise Phenotype Improvement | 25% | 34% | 33% |
Key Findings
- Nirmatrelvir–ritonavir treatment for up to 25 days did not improve long COVID symptoms compared to placebo.
- Among cognitive dysfunction patients, 58% improved with 25 days of treatment versus 55% with placebo.
- For autonomic dysfunction, 62% improved with 25 days of treatment compared to 70% with placebo.
- Only 25% of patients with exercise phenotype improved with the 25-day regimen compared to 33% with placebo.
- No new safety signals were identified, with serious adverse events occurring in 4% of patients across treatment groups.
- Subgroup analyses showed no differential treatment effects based on vaccination status, race, or sex.
Clinical Implications
The findings indicate that extended antiviral therapy with nirmatrelvir–ritonavir did not improve long COVID symptoms.
Conclusion
The RECOVER-VITAL trial results indicate that nirmatrelvir–ritonavir does not provide significant benefits for long COVID symptoms.
Related Resources & Content
- Baden LR, et al., The Lancet Infectious Diseases, 2026 -- Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial
- MDSpire News — Antivirals Speed COVID Recovery in Outpatients
- mdspire news — Repurposed drugs offer no sustained benefit for long COVID fatigue
- JAMA Network Open — Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients
- The Journal of Infectious Diseases — Targeting Cytomegalovirus Viremia: Implications for Non-Cytomegalovirus Syndromes Beyond Transplantation
- Long COVID Clinical Guidance | Long COVID | CDC
- Antivirals Speed COVID Recovery in Outpatients
- Repurposed drugs offer no sustained benefit for long COVID fatigue
- Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial - ScienceDirect
- Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
